Qualit-E-SpeakPharma-Insert
X

Find FDA Investigational New Drug (IND) Submissions for Cardiology/Vascular Diseases

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MAT9001

            Therapeutic Area: Cardiology/Vascular Diseases

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: BTIG

            Deal Size: $30.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 09, 2020

            Details:

            Matinas BioPharma anticipates using the net proceeds from the offering primarily for ongoing development for its product candidates, namely MAT9001, and its lipid nano-crystal (“LNC”) platform delivery technology